Aska Pharmaceutical Co. Ltd., a subsidiary of Aska Pharmaceutical Holdings Co. Ltd., and Red Arrow Therapeutics Inc. have signed a joint research agreement to develop a new treatment for preeclampsia using advanced nanotechnology.
At the ongoing ACS meeting in New Orleans, Rezubio Pharmaceuticals Co. Ltd. detailed the discovery and preclinical evaluation of novel small-molecule gut-restricted GPR40 agonists using membrane-anchored drug (MADD) design.
LX-101 from Lirum Therapeutics Inc. is an insulin-like growth factor 1 receptor (IGF-1R) inhibitor consisting of an IGF-1 variant coupled to a cytotoxic methotrexate payload. There are several aggressive cancer types of unmet need that have altered IGF-1R pathways and/or high IGF-1R expression, which correlates with poor prognosis.
To Steve Hyman, the manual that clinicians currently use to diagnose mental disorders is an active obstacle to getting a scientific understanding of those disorders. Hyman, who is director of the Stanley Center for Psychiatric Research at the Broad Institute, MIT and Harvard, and a former director of the National Institute of Mental Health (NIMH), listed multiple weaknesses of the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM), whose diagnoses, he said, are “arbitrary, rigid, life-stage and context-insensitive,” as well as blind to the fact that mental disorders exist along a continuum.
Patients with amyotrophic lateral sclerosis (ALS) have a median survival of 2 to 5 years. There are 3 FDA-approved drugs for ALS (riluzole, edaravone and Relyvrio [phenylbuturate/taurursodiol]), but they only lead to modest benefit. There are several pathways involved in the disease, but all of them lead to neuroinflammation.
Scientists at Taipei Medical University in Taiwan have developed a compound that could prevent resistance to temozolomide in the chemical treatment of glioblastoma.
Precisio Biotix Therapeutics Inc. has entered into an agreement with Mayo Clinic that will include co-development of novel precision antibacterials targeting indications prone to antimicrobial-resistant (AMR) infections. Precisio creates lower cost novel precision biological antibacterials with a focus on lung and skin infections.
The use of latency reversing agents is useful for reducing the HIV reservoir, but their effect on infected cells isolated from untreated people with HIV is still unknown.
Senisca Ltd., a spinout from the University of Exeter, has raised an additional £3.7 million (US$4.7 million) in funding to support the development of RNA-based senotherapeutics to treat age-related disease.
RSS
